Test Price
2,800 AED✅ Home Collection Available
REEP1 Gene (SPG31) Genetic Test in Dubai | 2800 AED | DHA Licensed, NGS‑Based Diagnostic Assay
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Next‑Generation Sequencing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post‑Test Genetic Counselling by a DHA‑licensed Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The REEP1 Gene (SPG31) Genetic Test uses next‑generation sequencing (NGS) to detect pathogenic variants in the REEP1 gene, the most common cause of autosomal dominant hereditary spastic paraplegia type 31. This assay confirms a clinical diagnosis, enables family risk assessment, and supports reproductive planning under DHA‑mandated genetic counselling protocols.
| Parameter | Our REEP1 NGS Test | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Technology | Next‑Generation Sequencing (NGS) | Sanger Sequencing |
| Mutation Coverage | All coding exons, splice sites, copy‑number variants | Selected exons; limited CNV detection |
| Turnaround Time | 3‑4 Weeks | 6‑12 Weeks |
| Clinical Sensitivity | >99% for point mutations and indels | ~95% |
| Post‑Test Counselling | Included (DHA‑licensed genetic counsellor) | Often absent |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist, I recommend this test for adults and children with progressive lower‑limb spasticity and a family history suggestive of hereditary spastic paraplegia. A positive result empowers clinical management and informed family planning, but all results must be correlated with the patient’s phenotype because some variants remain of uncertain significance. Your treating physician will integrate this genetic data with your full clinical picture and provide mandatory post‑test counselling.”
– Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Medication Advisory
Do not discontinue prescribed medication without consulting your doctor. This genetic test does not replace ongoing neurological care or clinical management by your specialist.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients with a confirmed SPG31 diagnosis by an alternate CLIA‑certified method; individuals who decline pre‑ and post‑test genetic counselling.
- Emergency Red Flags – Seek immediate medical help if you experience: sudden severe muscle weakness, respiratory difficulty, loss of bladder/bowel control, or acute vision changes.
Patient FAQ & Clinical Guidance
1. What is the REEP1 gene and how does it cause SPG31?
The REEP1 gene provides instructions for a protein that shapes the endoplasmic reticulum; mutations disrupt neuronal function in the corticospinal tracts, leading to hereditary spastic paraplegia type 31. Nearly all pathogenic variants follow an autosomal dominant inheritance pattern, meaning one altered copy suffices to cause the disease. The test screens for sequence changes and small deletions/duplications to support a definitive diagnosis and family screening.
2. Who should consider this genetic test?
Individuals with unexplained progressive spasticity in the legs, a family history of hereditary spastic paraplegia, or relatives of a known REEP1 mutation carrier are ideal candidates. It is also indicated for at‑risk couples undergoing preconception genetic screening under DHA genetic counselling guidelines. A pre‑test genetic counselling session is mandatory to review the pedigree and test implications.
3. What are the sample requirements and turnaround time?
We accept 2‑3 mL of whole blood in an EDTA tube, extracted DNA, or a single drop of blood on an FTA card. Results are delivered within 3 to 4 weeks. The pre‑test phase includes a mandatory genetic counselling session to construct a pedigree of family members affected by REEP1‑related SPG31. Home collection by a DHA‑licensed phlebotomist is available daily between 8 AM and 11 PM.
UAE Regulatory & Data Privacy Adherence
This test is performed at DNA Labs UAE, a DHA‑licensed facility (License No. 1143). All genetic data are handled in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. Your privacy is paramount; results are shared only with you and your designated physician.
Clinical & Logistical Metadata
| Test Name | REEP1 Gene (SPG31) Genetic Test – NGS |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (2–3 mL EDTA), extracted DNA, or FTA card |
| Methodology Used | Next‑Generation Sequencing (NGS) – full coding exons, splice sites, CNV analysis |
| ICD-10-CM Code | G11.4 |
| LOINC Code | 81262-2 |
| DHA Facility License & Laboratory Address | License No. 1143 – DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians